How I do it – MRT bei neurodegenerativen Erkrankungen mit führender Demenzsymptomatik – Workflow und Bildauswertung

Die zerebrale MRT hat einen hohen Stellenwert in der Demenzdiagnostik. Das Erkrankungsspektrum ist vielfältig und weist oft Überlappungen und Mischformen auf. Standardisierte spezifische neurodegenerative MRT-Protokolle sowohl mit visuellen, semiquantitativen als auch mit automatisierten, quantitativ-volumetrischen Auswertungen helfen dabei, globale und regionale Atrophiemuster zu erkennen und auch im Verlauf zu bewerten.

• Literatur

• 1 Hejl A, Høgh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry 2002; 73: 390-394
• 2 Urbach H, Egger K. MRT bei neurodegenerativen Erkrankungen. Fortschr Neurol Psychiatr 2020; 88: 266-284
• 3 Horger M, Gohla G, Bender B. et al. [Patterns of regional brain atrophy and quantification methods in different types of neurodegenerative diseases with leading dementia symptomatology]. Rofo 2023;
• 4 Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007; 20: 380-385
• 5 Klöppel S, Peter J, Ludl A. et al. Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study. J Alzheimers Dis 2015; 47: 939-954
• 6 Weder ND, Aziz R, Wilkins K. et al. Frontotemporal dementias: a review. Ann Gen Psychiatry 2007; 6: 15
• 7 Rabinovici GD, Carrillo MC, Forman M. et al. Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development. Alzheimers Dement (N Y) 2017; 3: 83-91
• 8 Lopera F, Marino C, Chandrahas AS. et al. Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. Nat Med 2023; 29: 1243-1252
• 9 Sims JR, Zimmer JA, Evans CD. et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023; 330: 512-527
• 10 Cohen S, van Dyck CH, Gee M. et al. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer’s Disease. J Prev Alzheimers Dis 2023; 10: 771-777
• 11 Gifford DR, Holloway RG, Vickrey BG. Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia. Arch Intern Med 2000; 160: 2855-2862
• 12 Dormont D, Seidenwurm DJ. Dementia and Movement Disorders. Am J Neurorad 2008; 29: 204-206
• 13 Mathias JL, Burke J. Cognitive functioning in Alzheimer’s and vascular dementia: a meta-analysis. Neuropsych 2009; 23: 411-423
• 14 Targosz-Gajniak M, Siuda J, Ochudło S. et al. Cerebral white matter lesions in patients with dementia – from MCI to severe Alzheimer’s disease. J Neurol Sci 2009; 283: 79-82
• 15 Pasquier F, Leys D, Weerts JG. et al. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 1996; 36: 268-272
• 16 Scheltens P, Leys D, Barkhof F. et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-972
• 17 Enkirch SJ, Traschütz A, Müller A. et al. The ERICA Score: An MR Imaging-based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. Radiology 2018; 288: 226-333
• 18 Koedam ELGE, Lehmann M, van der Flier WM. et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011; 21: 2618-2625
• 19 Ferreira D, Cavallin L, Granberg T. et al. Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. Eur Radiol 2016; 26: 2597-2610
• 20 Dubois B, Feldman HH, Jacova C. et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-629
• 21 Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol 2017; 13: 457-476
• 22 Duong MT, Wolk DA. Limbic-predominant Age-related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers. Curr Neurol Neurosci Rep 2022; 22: 689-698
• 23 Whitwell JL, Jack CR, Kantarci K. et al. Imaging Correlates of Posterior Cortical Atrophy. Neurobiol Aging 2007; 28: 1051-1061
• 24 Shir D, Corriveau-Lecavalier N, Bermudez Noguera C. et al. Clinicoradiological and neuropathological evaluation of primary progressive aphasia. J Neurol Neurosurg Psychiatry 2024;
• 25 Hanseeuw BJ, Jacobs HIL, Schultz AP. et al. Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults. Neurology 2023; 101: e2533-e2544
• 26 Román GC, Tatemichi TK, Erkinjuntti T. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260
• 27 Feldman HH, Jacova C, Robillard A. et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 2008; 178: 825-836
• 28 Charidimou A, Boulouis G, Frosch MP. et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol 2022; 21: 714-725
• 29 McKeith IG, Boeve BF, Dickson DW. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89: 88-100
• 30 Constantinides VC, Paraskevas GP, Paraskevas PG. et al. Corticobasal degeneration and corticobasal syndrome: A review. Clin Park Relat Disord 2019; 1: 66-71
• 31 Gorno-Tempini ML, Hillis AE, Weintraub S. et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014
• 32 Rascovsky K, Hodges JR, Knopman D. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-2477